GENESIS Trial: Almost Ninety Percent of Multiple Myeloma Patients Were Able to Proceed to Transplantation

A recent article in Cancer Network announced that motixafortide met its primary endpoint in the GENESIS trial for multiple myeloma patients who were scheduled for stem cell transplantation. Often, the…

Continue Reading GENESIS Trial: Almost Ninety Percent of Multiple Myeloma Patients Were Able to Proceed to Transplantation